SavedAdd your journal

Journals / Türk Biyokimya Dergisi / 2020 / Cilt: 45 - Sayı: 6

Expression level of miRNAS in patients with gestational diabetes

[Gestasyonel Diyabet Hastalarinda miRNA Ekspresyon Düzeyleri]

Didem DERİCİ YILDIRIM
Şenay BALCI
Filiz ÇAYAN
Ayşegül GÖRÜR
Lülüfer TAMER
Pages
825–832
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This study aimsto investigate miRNAs expressed in maternal plasma todetect the availability as a biomarker in the diagnosis ofGDM.Methods: In this study, 30 pregnant women with GDMdiagnosed according to GDM American Diabetes Associationcriteria and 30 healthy pregnant women were includedand miRNA expression levels were investigated.Circulating 39 miRNAs were analyzed by qRT-PCR using96.96 Dynamic Array IFCs.Results: The findings showed that the expression level ofmiR-7-5p significantly upregulated when compared withhealthy pregnant women with gestational diabetes (foldchange:2.3, p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: Gestational diabetes mellitus (GDM), whichhas been identified for the first time during pregnancyand is defined as glucose intolerance of varying degrees,is one of the prediabetes states that are at risk fordeveloping type 2 diabetes.
📊
Key Findings & Data:MicroRNAs (miRNAs) areassociated with pregnancy complications and are evennecessary for the regulation of pancreatic developmentand glucose-induced insulin secretion.
💡
Conclusion & Impact:This study aimsto investigate miRNAs expressed in maternal plasma todetect the availability as a biomarker in the diagnosis ofGDM.Methods: In this study, 30 pregnant women with GDMdiagnosed according to GDM American Diabetes Associationcriteria and 30 healthy pregnant women were includedand miRNA expression levels were investigated.Circulating 39 miRNAs were analyzed by qRT-PCR using96.96 Dynamic Array IFCs.Results: The findings showed that the expression level ofmiR-7-5p significantly upregulated when compared withhealthy pregnant women with gestational diabetes (foldchange:2.3, p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background: Gestational diabetes mellitus (GDM), whichhas been identified for the first time during pregnancyand is defined as glucose intolerance of varying degrees,is one of the prediabetes states that are at risk fordeveloping type 2 diabetes. MicroRNAs (miRNAs) areassociated with pregnancy complications and are evennecessary for the regulation of pancreatic developmentand glucose-induced insulin secretion. This study aimsto investigate miRNAs expressed in maternal plasma todetect the availability as a biomarker in the diagnosis ofGDM.Methods: In this study, 30 pregnant women with GDMdiagnosed according to GDM American Diabetes Associationcriteria and 30 healthy pregnant women were includedand miRNA expression levels were investigated.Circulating 39 miRNAs were analyzed by qRT-PCR using96.96 Dynamic Array IFCs.Results: The findings showed that the expression level ofmiR-7-5p significantly upregulated when compared withhealthy pregnant women with gestational diabetes (foldchange:2.3, p

Özet

Amaç: Gebelikte değişen derecelerde glikoz intoleransı olarak tanımlanan gestasyonel diabetes mellitus (GDM), tip two diyabet oluşturma riski bulunduran prediyabet durumlarından biridir. Pankreas gelişimi ve glikoza bağlı insülin sekresyonunun düzenlenmesinde rol alan mikro- RNA’lar (miRNA’lar), aynı zamanda gebelik ile ilgili komplikasyonlar ile de ilişkilidirler. Bu çalışmanın amacı, maternal plazmada ifade edilen miRNA’ların GDM tanısında kullanılabilirliğini tespit etmektir. Yöntemler: Çalışmaya, Amerikan Diyabet Derneği kriterlerine göre GDM tanısı alan 30 gebe ve 30 sağlıklı gebe dahil edildi ve miRNA ekspresyon düzeyleri araştırıldı. Dolaşımdaki 39 miRNA’nın analizi, 96.96 Dynamic Array IFCs kullanılarak qRT-PCR cihazında gerçekleştirildi. Bulgular: Sağlıklı gebeler ile karşılaştırıldığında, GDM’li gebelerde miR-7-5p′nin ekspresyon düzeyinin, anlamlı derecede artmış olduğu bulundu (kat değişimi: 2.3, p

🔖

Cite This Article

YILDIRIM, D. D., BALCI, Ş., ÇAYAN, F., GÖRÜR, A., TAMER, L. (2022). Expression level of miRNAS in patients with gestational diabetes. Türk Biyokimya Dergisi, Cilt: 45 - Sayı: 6, 825–832. https://ajindex.com/articles/620781

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Rice GE, Illanes SE, Mitchell MD. Gestational diabetes mellitus: a positive predictor of type 2 diabetes. Int J Endocrinol 2012;2012.
  2. Petry CJ. Gestational diabetes: risk factors and recent advances in its genetics and treatment. Br J Nutr 2010;104:775–87
  3. Wang X, Li W, Ma L, Gao J, Liu J, Ping F, et al. Association study of the miRNA-binding site polymorphisms of CDKN2A/B genes with gestational diabetes mellitus susceptibility. Acta Diabetol 2015; 52:951–8
  4. Shi Z, Zhao C, Guo X, Ding H, Cui Y, Shen R, et al. Differential expression of microRNAs in omental adipose tissue from gestational diabetes mellitus subjects reveals miR-222 as a regulator of ERα expression in estrogen-induced insulin resistance. Endocrinology 2014;155:1982–90
  5. Liang Z, Dong M, Cheng Q, Chen D. Gestational diabetes mellitus screening based on the gene chip technique. Diabetes Res Clin Pract 2010;89:167–73
  6. Zhu Y, Tian F, Li H, Zhou Y, Lu J, Ge Q. Profiling maternal plasma microRNA expression in early pregnancy to predict gestational diabetes mellitus. Int J Gynaecol Obstet 2010;130:49–53
  7. Zhao Z, Moley KH, Gronowski AM. Diagnostic potential for miRNAs as biomarkers for pregnancy-specific diseases. Clin Biochem 2013;46:953–60
  8. Kumar M, Nath S, Prasad HK, Sharma GD, Li Y. MicroRNAs: a new ray of hope for diabetes mellitus. Protein Cell 2012;3:726–38
  9. Poy MN, Hausser J, Trajkovski M, Braun M, Collins S, Rorsman P, et al. miR-375 maintains normal pancreatic α- and β-cell mass. Proc Natl Acad Sci USA 2009;106:5813–18
  10. Laganà AS, Vitale SG, Sapia F, Valenti G, Corrado F, Padula F, et al. miRNA expression for early diagnosis of preeclampsia onset: hope or hype? J Matern Fetal Neonatal Med 2017;5:1–5
  11. Lynn FC, Skewes-Cox P, Kosaka Y, McManus MT, Harfe BD. MicroRNA expression is required for pancreatic islet cell genesis in the mouse. Diabetes 2007;56:2938–45
  12. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova- Agadjanyan EL, et al. CirculatingmicroRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008;105: 10513–8
  13. American Diabetes A. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010;33(1 Suppl):62–9
  14. Balci S, Ayaz L, Gorur A, Yildirim HY, Akbayir S, Dogruer Unal N, et al. microRNA profiling for early detection of nonmelanoma skin cancer. Clin Exp Dermatol 2016;41:346–51
  15. Mestdagh P, VanVlierberghe P, DeWeer A, Muth D, Westermann F, Speleman F,